Low urine pH: a novel feature of the metabolic syndrome.

BACKGROUND AND OBJECTIVES The metabolic syndrome is associated with alterations in renal function. An overly acidic urine has been described as a renal manifestation of the metabolic syndrome in patients with kidney stone disease. This study examined the association between the metabolic syndrome and urine pH in individuals without a history of nephrolithiasis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS A total of 148 adults who were free of kidney stones were evaluated in this outpatient cross-sectional study. Height, weight, BP, fasting blood, and 24-h urine chemistries were obtained. Urine pH was measured by pH electrode. The following features of the metabolic syndrome were evaluated: BP; body mass index; and serum triglyceride, glucose, and HDL cholesterol concentrations. The degree of insulin resistance was assessed by the homeostasis model assessment of insulin resistance. RESULTS Participants with the metabolic syndrome had a significantly lower 24-h urine pH compared with participants without the metabolic syndrome. Mean 24-h urine pH, adjusted for age, gender, creatinine clearance, and 24-h urine sulfate, decreased from 6.15, 6.10, 5.99, 5.85, to 5.69 with increasing number of metabolic syndrome abnormalities. An association was observed between 24-h urine pH and each metabolic feature. After adjustment for age, gender, creatinine clearance, urine sulfate, and body mass index, a significant inverse relationship was noted between 24-h urine pH and the degree of insulin resistance. CONCLUSIONS An unduly acidic urine is a feature of the metabolic syndrome and is associated with the degree of insulin resistance.

[1]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[2]  E. Ritz Metabolic syndrome: an emerging threat to renal function. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[3]  G. Curhan,et al.  Body size and 24-hour urine composition. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  M. Daudon,et al.  Type 2 diabetes increases the risk for uric acid stones. , 2006, Journal of the American Society of Nephrology : JASN.

[5]  B. Adams-Huet,et al.  Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. , 2006, Journal of the American Society of Nephrology : JASN.

[6]  Francesco Locatelli,et al.  Renal manifestations in the metabolic syndrome. , 2006, Journal of the American Society of Nephrology : JASN.

[7]  L. Lind,et al.  Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study , 2006, BMJ : British Medical Journal.

[8]  M. Daudon,et al.  Influence of body size on urinary stone composition in men and women , 2006, Urological Research.

[9]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[10]  Paul Zimmet,et al.  The metabolic syndrome – Authors' reply , 2005, The Lancet.

[11]  E. Reisin,et al.  Kidney disease and the metabolic syndrome. , 2005, The American journal of the medical sciences.

[12]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[13]  G. Chertow,et al.  Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. , 2005, Journal of the American Society of Nephrology : JASN.

[14]  S. Grundy,et al.  The metabolic syndrome , 2003, The Lancet.

[15]  Nathan D. Wong,et al.  Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults , 2004, Circulation.

[16]  D. Albala,et al.  Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. , 2004, The Journal of urology.

[17]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[18]  J. Tuomilehto,et al.  Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. , 2004, Archives of internal medicine.

[19]  B. Adams-Huet,et al.  Association of urinary pH with body weight in nephrolithiasis. , 2004, Kidney international.

[20]  Jing Chen,et al.  The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults , 2004, Annals of Internal Medicine.

[21]  N. Abate,et al.  The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. , 2004, Kidney international.

[22]  S. Haffner,et al.  The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. , 2003, Diabetes care.

[23]  A. Mokdad,et al.  Trends in waist circumference among U.S. adults. , 2003, Obesity research.

[24]  G. Preminger,et al.  Biochemical profile of stone-forming patients with diabetes mellitus. , 2003, Urology.

[25]  O. Moe,et al.  Insulin activates Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence. , 2002, American journal of physiology. Renal physiology.

[26]  W. Frawley,et al.  Biochemical profile of idiopathic uric acid nephrolithiasis. , 2001, Kidney international.

[27]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[28]  T. Weinstein,et al.  Glomerular hemodynamics in severe obesity. , 2000, American journal of physiology. Renal physiology.

[29]  G. Reaven,et al.  Blood pressure, sodium intake, insulin resistance, and urinary nitrate excretion. , 1999, Hypertension.

[30]  J. Levy,et al.  Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program , 1998, Diabetes Care.

[31]  G. Reaven,et al.  The kidney: an unwilling accomplice in syndrome X. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  M. Yudkoff,et al.  Hormonal regulation of glutamine metabolism by OK cells. , 1995, Kidney international.

[33]  G. Reaven,et al.  Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. , 1991, JAMA.

[34]  L. Hamm,et al.  Ammonium transport in the kidney: new physiological concepts and their clinical implications. , 1991, Journal of the American Society of Nephrology : JASN.

[35]  P. Bennett,et al.  SEQUENTIAL CHANGES IN SERUM INSULIN CONCENTRATION DURING DEVELOPMENT OF NON-INSULIN-DEPENDENT DIABETES , 1989, The Lancet.

[36]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[37]  G. Reaven Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[38]  B. Finlayson,et al.  Stability of first dissociable proton of uric acid , 1974 .